{
    "clinical_study": {
        "@rank": "52059", 
        "arm_group": {
            "arm_group_label": "MK-1775/ Gemcitabine/ Radiation Therapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The investigators' long-term goal is to improve the survival of patients with pancreatic\n      cancer by enhancing the efficacy of gemcitabine-radiation by adding the Wee1 inhibitor\n      MK-1775."
        }, 
        "brief_title": "Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas", 
        "condition": "Adenocarcinoma of the Pancreas", 
        "condition_browse": {
            "mesh_term": "Adenocarcinoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have pathologically confirmed adenocarcinoma of the pancreas.\n\n          -  Patients will have unresectable disease, defined radiographically as >180 degrees\n             involvement of the superior mesenteric artery or celiac trunk or SMV/portal vein\n             impingement that cannot be surgically reconstructed, in the absence of distant\n             metastasis..\n\n          -  Patients must have a Zubrod performance status (measure of general well being that\n             ranges from 0 to 5 where 0 represents perfect health) of < 2.\n\n          -  Patients must have adequate organ function defined as follows: absolute neutrophil\n             count of \u2265 1500/mm3, platelets \u2265 100,000/mm3, serum creatinine \u2264 2 mg/dl, total\n             bilirubin \u2264 3, (with relief of biliary obstruction if present (PTC tube or\n             endobiliary stent)) and AST < 5 times the upper limit of normal.\n\n          -  Patients of reproductive potential must agree to use an effective contraceptive\n             method during participation in this trial and for 6 months after the trial.  Patients\n             must not be breastfeeding.\n\n          -  Patients must be aware of the investigational nature of the therapy and provide\n             written informed consent.\n\n          -  Patients must be at least 18 years old.\n\n        Exclusion Criteria:\n\n          -  Other serious uncontrolled concomitant systemic disorders or psychiatric condition\n             that would interfere with the safe delivery of protocol therapy.\n\n          -  A history of previous chemotherapy for pancreatic cancer or abdominal radiation\n             therapy.\n\n          -  The use of any investigational agent in the month before enrollment into the study.\n\n          -  Inability to discontinue a prescription or non-prescription drugs or other products\n             known to be metabolized by CYP3A4, or to inhibit or induce CYP3A4 prior to Day 1 of\n             dosing and to withhold throughout the study until 2 weeks after the last dose of\n             study medication.  Medications of particular concern are the following inhibitors of\n             CYP3A4: azole antifungals (ketoconazole itraconazole, fluconazole and voriconazole),\n             macrolide antibiotics (erythromycin, clarithromycin), cimetidine, aprepitant, HIV\n             protease inhibitors, nefazodone and the following inducers of CYP3A4: phenytoin,\n             barbiturates and rifampicin. Substrates of CYP3A4 include statins (lovastatin,\n             simvastatin), midazolam, terfenadine, astemizole, and cisapride."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01916551", 
            "nct_id": "NCT02037230", 
            "org_study_id": "UMCC 2013.094", 
            "secondary_id": "HUM00079048"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-1775/ Gemcitabine/ Radiation Therapy", 
                "description": "MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .", 
                "intervention_name": "MK-1775", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MK-1775/ Gemcitabine/ Radiation Therapy", 
                "description": "Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MK-1775/ Gemcitabine/ Radiation Therapy", 
                "description": "52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.", 
                "intervention_name": "Radiation Therapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pancrelipase", 
                "Gemcitabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "email": "tsl@umich.edu", 
                "last_name": "Theodore Lawrence, M.D., Ph.D.", 
                "phone": "734-647-9955"
            }, 
            "facility": {
                "address": {
                    "city": "Ann Arbor", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48109"
                }, 
                "name": "University of Michigan Hospital"
            }, 
            "investigator": {
                "last_name": "Theodore Lawrence, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "12A DOSE ESCALATION TRIAL OF THE Wee1 INHIBITOR MK1775, IN COMBINATION WITH GEMCITABINE (+RADIATION) FOR PATIENTS WITH UNRESECTABLE ADENOCARCINOMA OF THE PANCREAS", 
        "overall_contact": {
            "email": "tsl@umich.edu", 
            "last_name": "Theodore Lawrence, M.D., Ph.D.", 
            "phone": "734-647-9955"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan Cancer Center", 
            "last_name": "Theodore Lawrence, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "At the end of the trial, once all evaluable subjects have completed observation, p(DLT/d) will be calculated for each dose using the tite-CRM method (one parameter logistic regression model with prior distribution on the parameter alpha).", 
            "measure": "Maximum Tolerated Dose (MTD) of MK-1775 when used concurrently with gemcitabine and gemcitabine-radiation.", 
            "safety_issue": "Yes", 
            "time_frame": "36 months post treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037230"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Michigan Cancer Center", 
            "investigator_full_name": "Theodore S. Lawrence, MD, PhD", 
            "investigator_title": "Isadore Lampe Collegiate Professor of Radiation Oncology, Chair, Department of Radiation Oncology and Professor of Radiation Oncology, Medical School", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall survival (OS) will be summarized by Kaplan-Meier curves and characterized by descriptive statistics such as median OS.", 
                "measure": "Percent Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "1 year post treatment"
            }, 
            {
                "description": "During the first cycle of treatment, patients will undergo 2 biopsies:  3 h after treatment with gemcitabine (but before MK-1775), and 2 hours after MK-1775.  WEE1 signaling will be assessed using immunohistochemistry (IHC) to measure phosphorylation of various markers including Cdk1 (Y15). Inhibition will be quantified as the within subject change in the above markers between the two biopsy timepoints. Descriptive statistics of inhibition across subjects (for each marker) will be calculated and reported by dose level.", 
                "measure": "Proportion of patients with phosphorylation inhibition of greater than 0", 
                "safety_issue": "No", 
                "time_frame": "First Cycle of Treatment"
            }, 
            {
                "measure": "Time from date of registration to date of documented disease progression", 
                "safety_issue": "No", 
                "time_frame": "1 year post treatment"
            }
        ], 
        "source": "University of Michigan Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Michigan Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}